VRCA|Verrica Pharmaceuticals Inc|Price:6.910|Chg%:0.30

More Details of Verrica Pharmaceuticals Inc Company

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).

Verrica Pharmaceuticals Inc Info



Ticker SymbolVRCA

Company nameVerrica Pharmaceuticals Inc

IPO dateJun 15, 2018

CEORieger (Jayson)

Number of employees71

Security typeOrdinary Share

Fiscal year-endJun 15

Address44 West Gay Street

CityWEST CHESTER

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code19380

Phone14844533300

Websitehttps://verrica.com/

Ticker SymbolVRCA

IPO dateJun 15, 2018

CEORieger (Jayson)

Company Executives of Verrica Pharmaceuticals Inc



Name

Name/Position

Position

Shareholding

Change

Dr. Jayson Rieger

President, Chief Executive Officer, Director

183.30K

+94311.00%

Mr. David Zawitz

Chief Operating Officer

21.00K

+10000.00%

Dr. Noah L. Rosenberg, M.D.

Chief Medical Officer

2.36K

+2357.00%

Dr. Diem Nguyen, Ph.D.

Independent Director

10.00

--

Dr. Gavin Corcoran

Independent Director

2.00

--

Mr. Paul B. Manning

Chairman of the Board

--

Mr. Mark A. Prygocki, Sr.

Independent Director

--

Dr. Lawrence Eichenfield, M.D.

Independent Director

--

Mr. John J. Kirby

Interim Chief Financial Officer, Interim Principal Financial Officer

--

Name

Name/Position

Position

Shareholding

Change

Dr. Jayson Rieger

President, Chief Executive Officer, Director

183.30K

+94311.00%

Mr. David Zawitz

Chief Operating Officer

21.00K

+10000.00%

Dr. Noah L. Rosenberg, M.D.

Chief Medical Officer

2.36K

+2357.00%

Dr. Diem Nguyen, Ph.D.

Independent Director

10.00

--

Dr. Gavin Corcoran

Independent Director

2.00

--

Mr. Paul B. Manning

Chairman of the Board

--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.

Relevant data have not been disclosed by the company yet.

By Business

By Region

Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Sat, Jan 31

Shareholders

Shareholder Types

Shareholders

Proportion

Manning (Paul B.)

28.51%

BKB Growth Investments LLC

20.94%

Caligan Partners, LP

5.78%

Affinity Asset Advisors LLC

4.42%

Armistice Capital LLC

4.00%

Other

36.35%

Shareholders

Proportion

Manning (Paul B.)

28.51%

BKB Growth Investments LLC

20.94%

Caligan Partners, LP

5.78%

Affinity Asset Advisors LLC

4.42%

Armistice Capital LLC

4.00%

Other

36.35%

Shareholder Types

Shareholders

Proportion

Individual Investor

31.47%

Corporation

21.10%

Hedge Fund

14.84%

Investment Advisor/Hedge Fund

2.43%

Investment Advisor

1.54%

Venture Capital

0.18%

Family Office

0.11%

Research Firm

0.02%

Other

28.32%

Institutional Shareholding



Updated: Thu, Jan 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q4

174

3.04M

19.01%

-494.27K

2025Q3

171

2.46M

26.06%

-1.46M

2025Q2

183

8.91M

96.35%

+3.15M

2025Q1

194

69.94M

75.99%

+19.16M

2024Q4

191

70.39M

77.72%

+35.42M

2024Q3

179

29.67M

67.28%

-5.27M

2024Q2

173

33.68M

79.75%

-1.13M

2024Q1

171

34.51M

82.01%

-2.46M

2023Q4

170

35.04M

83.66%

+1.56M

2023Q3

172

32.74M

78.91%

-2.85M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Manning (Paul B.)

4.56M

28.51%

+1.42M

+45.27%

Nov 25, 2025

BKB Growth Investments LLC

3.35M

20.94%

+2.75M

+460.29%

Nov 25, 2025

Caligan Partners, LP

923.91K

5.78%

--

Dec 26, 2025

Affinity Asset Advisors LLC

707.34K

4.42%

+707.34K

--

Nov 25, 2025

Armistice Capital LLC

639.19K

4%

-248.94K

-28.03%

Sep 30, 2025

Boothbay Fund Management, LLC

280.73K

1.76%

+280.73K

--

Sep 30, 2025

Stalfort (John A)

187.38K

1.17%

+23.81K

+14.56%

Apr 01, 2025

Rieger (Jayson)

183.30K

1.15%

+94.31K

+105.98%

Nov 25, 2025

The Vanguard Group, Inc.

225.21K

1.41%

+8.38K

+3.86%

Sep 30, 2025

Millennium Management LLC

71.99K

0.45%

-18.72K

-20.64%

Sep 30, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

iShares Micro-Cap ETF

0%

iShares Russell 2000 Growth ETF

0%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0%

Dimensional US Core Equity 1 ETF

0%

Global X Russell 2000 Covered Call ETF

0%

Invesco Dorsey Wright SmallCap Momentum ETF

0%

Avantis US Small Cap Equity ETF

0%

ProShares UltraPro Russell2000

0%

Global X Russell 2000 ETF

0%

iShares Russell 2000 ETF

0%

iShares Micro-Cap ETF

Proportion0%

iShares Russell 2000 Growth ETF

Proportion0%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

Proportion0%

Dimensional US Core Equity 1 ETF

Proportion0%

Global X Russell 2000 Covered Call ETF

Proportion0%

Invesco Dorsey Wright SmallCap Momentum ETF

Proportion0%

Avantis US Small Cap Equity ETF

Proportion0%

ProShares UltraPro Russell2000

Proportion0%

Global X Russell 2000 ETF

Proportion0%

iShares Russell 2000 ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

Jul 23, 2025

Merger

10→1

Date

Ex-dividend Date

Type

Ratio

Jul 23, 2025

Merger

10→1